Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Grade III Neuroendocrine Carcinoma”

57 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 57 results

Large-scale testing (Phase 3)Study completedNCT01298323
What this trial is testing

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Who this might be right for
Locally Advanced or Metastatic Medullary Thyroid CancerMedullary Thyroid Cancer
Sanofi 205
Testing effectiveness (Phase 2)Study completedNCT00445965
What this trial is testing

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Who this might be right for
Brain and Central Nervous System TumorsIntraocular MelanomaLung Cancer+7 more
Memorial Sloan Kettering Cancer Center 78
Testing effectiveness (Phase 2)Looking for participantsNCT04325425
What this trial is testing

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Who this might be right for
Neuroendocrine Carcinoma
Centre Hospitalier Universitaire Dijon 218
Testing effectiveness (Phase 2)Ended earlyNCT01215578
What this trial is testing

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Who this might be right for
Neuroendocrine TumorsPancreatic NeoplasmsAdvanced Disease+1 more
Assistance Publique - Hôpitaux de Paris 33
Early research (Phase 1)Ended earlyNCT02714374
What this trial is testing

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

Who this might be right for
Solid Organ Cancers
Andrew Lowy 5
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Not applicableUnknownNCT03896958
What this trial is testing

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

Who this might be right for
Cancer, All TypesCancer of LiverCancer of Stomach+42 more
SpeciCare 1,000
Early research (Phase 1)Looking for participantsNCT05039801
What this trial is testing

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Malignant Solid Neoplasm+35 more
M.D. Anderson Cancer Center 54
Testing effectiveness (Phase 2)UnknownNCT05113355
What this trial is testing

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Tumor Grade 3Neuroendocrine Carcinoma+1 more
Peking Union Medical College Hospital 23
Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH
Testing effectiveness (Phase 2)UnknownNCT04525638
What this trial is testing

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Who this might be right for
Neuroendocrine Tumours (NET)Neuroendocrine Carcinomas (NEC)
Fundación de investigación HM 30
Testing effectiveness (Phase 2)Study completedNCT02820857
What this trial is testing

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

Who this might be right for
Neuroendocrine Carcinomas
Hospices Civils de Lyon 153
Testing effectiveness (Phase 2)Study completedNCT03728361
What this trial is testing

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Who this might be right for
Grade I Neuroendocrine CarcinomaGrade II Neuroendocrine CarcinomaGrade III Neuroendocrine Carcinoma+9 more
Dwight Owen 55
Testing effectiveness (Phase 2)Study completedNCT03079440
What this trial is testing

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaTemozolomide+1 more
Asan Medical Center 31
Not applicableWithdrawnNCT00378781
What this trial is testing

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Who this might be right for
Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Temporarily pausedNCT05058651
What this trial is testing

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Who this might be right for
Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI) 189
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05385861
What this trial is testing

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Who this might be right for
GEP-NET
National Health Research Institutes, Taiwan 52
Not applicableStudy completedNCT00899496
What this trial is testing

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Who this might be right for
Cancer
Wake Forest University Health Sciences 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT04759911
What this trial is testing

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Who this might be right for
Malignant Thyroid Gland NeoplasmPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland Carcinoma+4 more
M.D. Anderson Cancer Center 30
Next Page
40
116